Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.45 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | CNR2 | P34972 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21542545 | 1.00 | EPHX1 (0.48) | EPHX1SMN1; SMN2KMT2AATMLMNA | |
| SCHEMBL21542539 | 1.00 | EPHX1 (0.48) | EPHX1SMN1; SMN2KMT2AATMLMNA | |
| SCHEMBL4532015 | 0.93 | CA1 (0.55) | EPHX1SMN1; SMN2KMT2AATMLMNA | |
| SCHEMBL597442 | 0.89 | IDO1 (0.46) | SMN1; SMN2KMT2AATMLMNAALDH1A1 | |
| SCHEMBL11640483 | 0.89 | KMT2A (0.51) | EPHX1KMT2AATMALDH1A1CA12 | |
| SCHEMBL8671295 | 0.87 | SMN1; SMN2 (0.58) | SMN1; SMN2LMNACA12CA1CA2 | |
| SCHEMBL11602058 | 0.85 | CYP19A1 (0.49) | EPHX1SMN1; SMN2KMT2ALMNAHPGD | |
| Diphenylmethanol SCHEMBL10868602 | 0.84 | SMN1; SMN2 (0.61) | SMN1; SMN2LMNACA12CA1CA2 | |
| Diphenylmethanol SCHEMBL41571 | 0.84 | SMN1; SMN2 (0.61) | SMN1; SMN2LMNACA12CA1CA2 | |
| Diphenylmethanol SCHEMBL6434457 | 0.84 | SMN1; SMN2 (0.61) | SMN1; SMN2LMNACA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117362236-B | Synthesis method of flumazenil | 江苏远恒药业有限公司 | 2024-05-03 | — | — | CN | claimed |
| CN-117362236-A | Synthesis method of flumazenil | 江苏远恒药业有限公司 | 2024-01-09 | — | — | CN | claimed |
| CN-112517060-B | Catalyst, application and synthesis method of 4-hydroxycoumarin derivative | 山东农业大学 | 2022-03-25 | — | — | CN | claimed |
| EP-2665703-B1 | ENANTIOMER (R) OF LAUFLUMIDE IN MEHR ALS 95%ee | NLS PHARMA AG (CH) | 2017-12-06 | — | — | EP | claimed |
| EP-2665703-A1 | LAUFLUMIDE AND THE ENANTIOMERS THEREOF, METHOD FOR PREPARING SAME AND THERAPEUTIC USES THEREOF | Assistance Publique Hôpitaux De Paris (FR) | 2013-11-27 | — | — | EP | claimed |
| US-20130295196-A1 | LAUFLUMIDE AND THE ENANTIOMERS THEREOF, METHOD FOR PREPARING SAME AND THERAPEUTIC USES THEREOF | ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS (FR) | 2013-11-07 | — | — | US | claimed |
| WO-2012098235-A1 | LAUFLUMIDE AND THE ENANTIOMERS THEREOF, METHOD FOR PREPARING SAME AND THERAPEUTIC USES THEREOF | ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (FR) | 2012-07-26 | — | — | WO | claimed |
| EP-0686635-A1 | Pyridylthiazolidinecarboxylic acid amide derivatives, their preparation and their therapeutic uses | Sankyo Company Limited (JP) | 1995-12-13 | — | — | EP | claimed |
| US-5470851-A | Antihistamine, anticoagulants | SANKYO COMPANY, LIMITED (JP) | 1995-11-28 | — | — | US | claimed |
| EP-0549364-A1 | Pyridylthiazolidinecarboxylic acid amide derivatives, their preparation and their therapeutic uses | Sankyo Company Limited (JP) | 1993-06-30 | — | — | EP | claimed |
| EP-4583876-A1 | COMBINATION OF A T CELL THERAPY AND CONTINUOUS OR INTERMITTENT DGK INHIBITOR DOSING | Juno Therapeutics, Inc. (US) | 2025-07-16 | — | — | EP | disclosed |
| CN-120152717-A | Combination of T cell therapy and continuous or intermittent DGK inhibitor administration | 朱诺治疗学股份有限公司 | 2025-06-13 | — | — | CN | disclosed |
| CN-112654621-B | Substituted naphthyridinone compounds useful as T cell activators | 百时美施贵宝公司 | 2024-05-14 | — | — | CN | disclosed |
| CN-117362236-B | Synthesis method of flumazenil | 江苏远恒药业有限公司 | 2024-05-03 | — | — | CN | disclosed |
| CN-117362236-B | Synthesis method of flumazenil | 江苏远恒药业有限公司 | 2024-05-03 | — | — | CN | disclosed |
| US-4916058-A | CHROMOGENS | KYOWA MEDEX CO., LTD. (JP) | 1990-04-10 | — | — | US | disclosed |
| US-4874765-A | 1,4-Disubstituted piperazines having dopaminergic activity | RICHTER GEDEON VEGYESZETI GYAR (HU) | 1989-10-17 | — | — | US | disclosed |
| EP-0243903-A1 | Optionally substituted 1-(omega[bis(phenyl)-alcoxy]-alkyl)-4-(alkenyl)piperazines and -4-(alkynyl)piperazines, process for their preparation and medicines containing them | Richter Gedeon Vegyészeti Gyár R.T. (HU) | 1987-11-04 | — | — | EP | disclosed |
| EP-0124287-A2 | Method and test composition for determination of hydrogen peroxide | Kyowa Medex Co. Ltd. (JP) | 1984-11-07 | — | — | EP | disclosed |
| US-4202896-A | DOPAMINERGIC ACTIVITY | GIST-BROCADES N.V. (NL) | 1980-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130295196-A1 | LAUFLUMIDE AND THE ENANTIOMERS THEREOF, METHOD FOR PREPARING SAME AND THERAPEUTIC USES THEREOF | HCRTR2, HNMT, CYP2U1 | EPHX1 530/4885SMN1; SMN2 656/4885KMT2A 110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.